Form 4 for ARQT Arcutis Biotherapeutics, Inc.

Accepted 2024-05-20 00:00:00 ET · period of report 2024-05-16 · accession 0001787306-24-000081 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
	2024-05-20	2024-05-16	ARQT	Edwards Larry Todd	SVP Chief Commercial Off	A - Grant	$0.00	+60.0K	148.0K	+68%	$0
	2024-05-20	2024-05-17	ARQT	Edwards Larry Todd	SVP Chief Commercial Off	S - Sale	$8.98	-7,640	140.4K	-5%	-$68.6K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2024-05-16	A	A	60,000	$0.00	148,000	D	—	—	(F1) Represents Restricted Stock Units ("RSUs"), initially granted on February 22, 2024, in which the shares were subject to a performance-based vesting condition, which was deemed satisfied on May 16, 2024 (the "Vesting Commencement Date"). Therefore, 50% of the shares vested on May 16, 2024 and the remaining 50% of the shares vest on May 16, 2025, subject to the Reporting Person's continued service with the Company through the applicable vesting date.
2	Common	Common Stock	2024-05-17	S	D	7,640	$8.98	140,360	D	—	—	(F3) The transaction was executed in multiple trades in prices ranging from $8.76 to $9.115, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.